These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24207125)

  • 21. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
    Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
    J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.
    Nagata T; Shirakawa K; Kobayashi N; Shiheido H; Tabata N; Sakuma-Yonemura Y; Horisawa K; Katahira M; Doi N; Yanagawa H
    PLoS One; 2014; 9(10):e109163. PubMed ID: 25275651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
    Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
    Hu G; Xu S; Wang J
    Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
    Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
    Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
    McCoy MA; Gesell JJ; Senior MM; Wyss DF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P53 mdm2 inhibitors.
    Khoury K; Dömling A
    Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
    Patil SP
    Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.
    Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
    Sci Rep; 2017 Nov; 7(1):15600. PubMed ID: 29142290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.
    Samanta S; Mukherjee S
    J Comput Aided Mol Des; 2017 Oct; 31(10):891-903. PubMed ID: 28871352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding Ensembles of
    Lang L; Perez A
    Molecules; 2021 Jan; 26(1):. PubMed ID: 33401765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.
    Riedinger C; Endicott JA; Kemp SJ; Smyth LA; Watson A; Valeur E; Golding BT; Griffin RJ; Hardcastle IR; Noble ME; McDonnell JM
    J Am Chem Soc; 2008 Nov; 130(47):16038-44. PubMed ID: 18959403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of a novel MDM2 binding peptide based on the p53 family.
    Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
    Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
    Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.